当前位置：
X-MOL 学术
›
Blood Cancer J.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis.
Blood Cancer Journal ( IF 12.8 ) Pub Date : 2022-04-19 , DOI: 10.1038/s41408-022-00662-0 Ricardo D Parrondo 1 , Keren Sam 1 , Ahsan Rasheed 1 , Victoria Alegria 1 , Taimur Sher 1 , Vivek Roy 1 , Asher Chanan-Khan 1, 2, 3 , Sikander Ailawadhi 1, 2
中文翻译：
复发/难治性多发性骨髓瘤患者接受 idecabtagene vicleucel 治疗后的后续抗骨髓瘤治疗：单中心分析。
更新日期：2022-04-19
Blood Cancer Journal ( IF 12.8 ) Pub Date : 2022-04-19 , DOI: 10.1038/s41408-022-00662-0 Ricardo D Parrondo 1 , Keren Sam 1 , Ahsan Rasheed 1 , Victoria Alegria 1 , Taimur Sher 1 , Vivek Roy 1 , Asher Chanan-Khan 1, 2, 3 , Sikander Ailawadhi 1, 2
Affiliation
中文翻译：
复发/难治性多发性骨髓瘤患者接受 idecabtagene vicleucel 治疗后的后续抗骨髓瘤治疗：单中心分析。
京公网安备 11010802027423号